Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials.

ABSTRACT: Fluvoxamine is widely prescribed as an antidepressant. Recent studies show the drug may have a clinical benefit in treating COVID-19. We aimed to perform a meta-analysis of the existing randomized trials of fluvoxamine compared with placebo on the early treatment of COVID-19 patients. We included only randomized clinical trials enrolling ambulatory patients with early-stage disease (symptoms > 7 days) for the prevention of hospitalization. We searched MEDLINE, and clinicaltrials.gov databases to identify trials and extract data with clarifications from the study investigators. We performed a fixed-effects meta-analysis and sensitivity analyses via R to evaluate the pooled estimate of hospitalization. We included three randomized trials: STOP COVID 1 and 2, and the TOGETHER Trial. The studi

SUBMITTER: Guo CM 

PROVIDER: S-EPMC9128689 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature